Mar 06,2018

Fit4D Announces Expansion with Humana to Deliver Personalized Diabetes Coaching to High-Risk Populations in South Florida

Fit4D (now named as Cecelia Health), a diabetes management company, announced a program expansion today with Humana Inc. (NYSE: HUM), a leading health and well-being company, to bring Fit4D’s personalized coaching to high-risk Humana members in Broward County, Florida. Fit4D established a partnership with Humana in April 2017 to provide its diabetes coaching solution to members in North and Central Florida. This new expansion is part of Humana’s Bold Goal initiative to make the Broward community 20% healthier by 2020, and will now serve more diabetes members in Florida.

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 07,2018

Tandem Diabetes Care Announces Upcoming Conference Presentations

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the following upcoming investor conferences: 38th Annual Cowen Health Care Conference in Boston, MA. The presentation will take place on Wednesday, March 14, 2018 at 8:00AM Eastern Time (5:00AM Pacific Time), and 28th Annual Oppenheimer Healthcare Conference in New York, NY. The presentation will take place on Wednesday, March 21, 2018 at 11:30AM Eastern Time (8:30AM Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 08,2018

Johns Hopkins Study Reveals Artificial Intelligence (AI)-Driven Mobile App Sweetch Reduces Blood Sugar Levels in Early Stage Diabetes Patients

Sweetch, the mobile-health app that helps prevent and improve outcomes in diabetes by encouraging long-term behavioral change, today revealed the outcomes of its clinical trial conducted at Johns Hopkins University. Directed by the university's Division of Endocrinology, Diabetes, & Metabolism, the study shows that using Sweetch significantly lowered A1C levels, a diabetes biomarker for blood sugar, increased physical activity and reduced weight for patients with early stage diabetes. Being active for 150 minutes a week and reducing weight by 5 to 7 percent has been proven to reduce the chances of developing diabetes by 58 percent. The full results of the study are published in the Journal of Medical Internet Research.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 12,2018

Medtronic Receives FDA Approval for Guardian Connect Continuous Glucose Monitoring (CGM) System for People Living with Diabetes

Medtronic plc, the global leader in medical technology, services and solutions, today announced it received U.S. Food and Drug Administration (FDA) approval for its Guardian Connect continuous glucose monitoring (CGM) system, for people with diabetes ages 14 to 75 years. The Guardian Connect system is the first smart standalone CGM system to help people with diabetes stay ahead of high and low glucose events. The Guardian Connect system empowers people using multiple daily injections (MDI) to more proactively manage their diabetes.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 14,2018

Overcome key challenges in daily diabetes therapy: Integration of latest technology and Personalised Diabetes Management promotes improved outcomes and more time in range

The Personalised Diabetes Management-ProValue study program was conducted ny Roche Diabetes Care with more than 900 patients treated in diabetes specialist and general medical practices in Germany. The results of this prospective, controlled and cluster-randomised study are of high relevance for both healthcare professionals and people with diabetes as they underline efficiency and effectiveness of the structured integrated Personalised Diabetes Management (iPDM) concept.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 14,2018

Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), announced that it will have a presence at three leading national diabetes congresses in Europe over the coming months, which are Diabetes UK Professional Conference (Diabetes UK), March 14-16 at ExCeL, London, Société Francophone du Diabète (SFD) Annual Conference, March 20-23 at Cité des Congrès de Nantes, France, and Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, May 9-12 at CityCube Berlin, Germany.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 14,2018

Introducing the new CGM by Metronom

Metronom Health, founded in 2010, recently announced that they are poised to bring a new CGM to the market. They are promising a product that is an improvement on existing technology, offering better accuracy and reliability, a longer and more convenient wear period, affordability, and a more comprehensive user interface.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 23,2018

Brighters year-end report 2017.

Fourth quarter, October–December 2017, results are as follows: Net sales amounted to SEK 576 thousand, Capitalized expenditure for development work reached SEK 12,390 thousand, Operating income amounted to SEK 13,827 thousand.

View Analyst & Ambassador Comments
Go to original news
Mar 26,2018

Brighter and FRISQ initiate partnership to strengthen the infrastructure for digital healthcare

Brighter and FRISQ have initiated a strategic partnership to strengthen the infrastructure and increase the information flow in the healthcare sector, as well as simplify the implementation of distance monitoring in diabetes care. The ambition is to provide a basis for better treatment of patients during the time between their hospital visits, through new digital services and mobile products.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Mar 27,2018

FDA Authorizes Marketing of the New Dexcom G6 CGM Eliminating the Need for Fingerstick Blood Testing for People with Diabetes

Dexcom is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up. The Dexcom G6 is indicated by the FDA for use as both a standalone CGM and for integration into automated insulin dosing (AID) systems. The powerful and revolutionary new Dexcom G6® is the first CGM to receive this classification by the FDA.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES